动脉瘤性蛛网膜下腔出血结局的中心与国家差异:SAHIT 数据库分析
基于 SAHIT 数据库中 5972 例 aSAH 患者(179 中心、20 国家)的随机临床试验数据,采用随机效应 logistic 回归分析发现,不良结局比例为 27%(n=1599),中心间存在显著差异(粗 MOR 1.26,95%CI 1.16-1.52;调整后 MOR 1.21,95%CI 1.11-1.44),但国家间差异无统计学意义(调整后 MOR 1.13,95%CI 1.00-1.40)。
要点
- aSAH 不良结局在中心间存在差异,调整患者特征与治疗时机后仍显著(MOR 1.21)。
- 国家间不良结局差异无统计学意义(调整后 MOR 1.13,95%CI 1.00-1.40)。
- 中心间差异不能由患者特征或动脉瘤治疗时机解释。
核心结论
- aSAH 后临床结局在不同中心间存在差异,且不能由患者特征或动脉瘤治疗时机解释。
- 国家间结局差异未达统计学意义。
- 需更近期数据确认医院间结局差异并探究潜在原因。
研究设计与样本
- 分析 SAHIT 数据库中 5972 例 aSAH 患者,来自 3 项不同治疗随机临床试验,涵盖 179 个中心和 20 个国家。
- 采用随机效应 logistic 回归,调整患者特征和动脉瘤治疗时机,估计中心间和国家间不良结局差异。
- 不良结局定义为 3 个月时 GOS 评分 1-3 或 mRS 评分 4-6。
- 中心间和国家间差异用中位比值比(MOR)量化。
主要发现
- 不良结局患者比例为 27%(n=1599)。
- 中心间差异显著:粗 MOR 1.26(95%CI 1.16-1.52),调整后 MOR 1.21(95%CI 1.11-1.44)。
- 国家间差异无统计学意义:调整后 MOR 1.13(95%CI 1.00-1.40)。
临床怎么用
- 提示临床中心间 aSAH 结局存在差异,应关注本院诊疗流程与质量改进。
- 国家层面差异不显著,跨中心比较时需考虑中心效应。
局限性
- 数据来自随机临床试验,可能不能完全反映真实世界实践。
- 需更近期数据确认医院间结局差异。
- 中心间差异的原因尚未明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Differences in clinical outcomes between centers and countries may reflect variation in patient characteristics, diagnostic and therapeutic policies, or quality of care. The purpose of this study was to investigate the presence and magnitude of between-center and between-country differences in outcome after aneurysmal subarachnoid hemorrhage (aSAH). METHODS: The authors analyzed data from 5972 aSAH patients enrolled in randomized clinical trials of 3 different treatments from the Subarachnoid Hemorrhage International Trialists (SAHIT) repository, including data from 179 centers and 20 countries. They used random effects logistic regression adjusted for patient characteristics and timing of aneurysm treatment to estimate between-center and between-country differences in unfavorable outcome, defined as a Glasgow Outcome Scale score of 1-3 (severe disability, vegetative state, or death) or modified Rankin Scale score of 4-6 (moderately severe disability, severe disability, or death) at 3 months. Between-center and between-country differences were quantified with the median odds ratio (MOR), which can be interpreted as the ratio of odds of unfavorable outcome between a typical high-risk and a typical low-risk center or country. RESULTS: The proportion of patients with unfavorable outcome was 27% (n = 1599). The authors found substantial between-center differences (MOR 1.26, 95% CI 1.16-1.52), which could not be explained by patient characteristics and timing of aneurysm treatment (adjusted MOR 1.21, 95% CI 1.11-1.44). They observed no between-country differences (adjusted MOR 1.13, 95% CI 1.00-1.40). CONCLUSIONS: Clinical outcomes after aSAH differ between centers. These differences could not be explained by patient characteristics or timing of aneurysm treatment. Further research is needed to confirm the presence of differences in outcome after aSAH between hospitals in more recent data and to investigate potential causes.
引用
- Dijkland SA, Jaja BNR, van der Jagt M, et al. Between-center and between-country differences in outcome after aneurysmal subarachnoid hemorrhage in the Subarachnoid Hemorrhage International Trialists (SAHIT) repository. J Neurosurg. 2019. PMID: 31443072. doi:10.3171/2019.5.JNS19483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。